share_log

iBio Inc | 8-K: Current report

iBio Inc | 8-K: Current report

iBio Inc | 8-K:重大事件
美股SEC公告 ·  07/09 16:06
Moomoo AI 已提取核心信息
On July 2, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the approval of new forms of award agreements by the company's Board. These agreements are designed for the grant of stock options and restricted stock units to directors, executive officers, employees, and consultants under iBio's 2023 Plan. The agreements include various terms and vesting criteria, with provisions detailing the exercise price payment methods and the treatment of awards upon termination of service for different reasons. Additionally, iBio Inc adopted an updated Code of Business Conduct and Ethics applicable to all directors, officers, and employees, replacing the previous code to better reflect the company's operations and mitigate risk. The full text of the Award Agreements and the updated Code are attached to the report as exhibits.
On July 2, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the approval of new forms of award agreements by the company's Board. These agreements are designed for the grant of stock options and restricted stock units to directors, executive officers, employees, and consultants under iBio's 2023 Plan. The agreements include various terms and vesting criteria, with provisions detailing the exercise price payment methods and the treatment of awards upon termination of service for different reasons. Additionally, iBio Inc adopted an updated Code of Business Conduct and Ethics applicable to all directors, officers, and employees, replacing the previous code to better reflect the company's operations and mitigate risk. The full text of the Award Agreements and the updated Code are attached to the report as exhibits.
2024年7月2日,ibio inc,一家在特拉华州注册的生物技术公司,向SEC提交8-k表格,报告公司董事会批准新形式的奖励协议。这些协议旨在根据ibio公司的2023计划向董事、高管、员工和顾问授予股票期权和限制性股票单位。该协议包括各种条款和归属条件,规定了行权价格支付方式以及不同原因服务终止时奖励的处理方式。此外,ibio inc采用了一份更新的适用于所有董事、高管和员工的商业行为准则和道德规范,以取代先前的准则,以更好地反映公司的运营并减少风险。奖励协议和更新的准则的全文展示在报告中作为展览品附加。
2024年7月2日,ibio inc,一家在特拉华州注册的生物技术公司,向SEC提交8-k表格,报告公司董事会批准新形式的奖励协议。这些协议旨在根据ibio公司的2023计划向董事、高管、员工和顾问授予股票期权和限制性股票单位。该协议包括各种条款和归属条件,规定了行权价格支付方式以及不同原因服务终止时奖励的处理方式。此外,ibio inc采用了一份更新的适用于所有董事、高管和员工的商业行为准则和道德规范,以取代先前的准则,以更好地反映公司的运营并减少风险。奖励协议和更新的准则的全文展示在报告中作为展览品附加。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息